This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurotoxicology  • Facial Plastic Surgery  • Cosmetic Surgery/ Procedures  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Carolyn H. Kwak, PA; Philip A. Hanna, MD; Joseph Jankovic, MD

Arch Neurol. 2000;57:1190-1193.

Objective  To evaluate the safety and efficacy of botulinum toxin A (BTX) injections in the treatment of tics in patients with Tourette syndrome (TS).

Background  BTX is an effective treatment for an increasing number of conditions characterized by abnormal muscle contractions. BTX may improve not only the motor component of tics, but also premonitory sensations that precede tics.

Methods  Thirty-five patients (30 male, 5 female) were treated with BTX in the sites of their most problematic tics. Response to BTX was based on a 0 to 4 clinical rating scale (0, no improvement, to 4, marked improvement in both severity and function). Questionnaires were administered to evaluate patients' impressions of overall efficacy and degree of benefit with premonitory sensations.

Results  Mean duration of tics prior to initial injection was 15.3 years (range, 1-62 years) and mean duration of follow-up was 21.2 months (range, 1.5-84 months). The mean peak effect response in 35 patients treated in 115 sessions was 2.8 (range, 0-4); the mean duration of benefit was 14.4 weeks (maximum, 45 weeks); and the mean latency to onset of benefit was 3.8 days (maximum, 10 days). Twenty-one (84%) of 25 patients with premonitory sensations derived marked relief of these symptoms (mean benefit, 70.6%). Total mean dose was 502.1 U (range, 15-3550 U); mean number of visits, 3.3 (range, 1-16); and mean dose per visit, 119.9 U (range, 15-273 U). Sites of injections were as follows: cervical or upper thoracic area (17), upper face (14), lower face (7), vocal cords (4), upper back and/or shoulder (3), scalp (1), forearm (1), leg (1) and rectus abdominis (1). Complications included neck weakness (4), dysphagia (2), ptosis (2), nausea (1), hypophonia (1), fatigue (1), and generalized weakness (1), which were all mild and transient.

Conclusions  Botulinum toxin A injections are an effective and well-tolerated treatment of tics. In addition to improving the motor component of tics, BTX also provides relief of premonitory sensations.

From the Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Tex (Ms Kwak and Drs Hanna and Jankovic), and the New Jersey Neuroscience Institute, JFK Medical Center, Edison, NJ (Dr Hanna).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(8):1241-1242.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Simpson et al.
Neurology 2008;70:1699-1706.
ABSTRACT | FULL TEXT  

Botulinum toxin in clinical practice
Jankovic
J. Neurol. Neurosurg. Psychiatry 2004;75:951-957.
ABSTRACT | FULL TEXT  

Cervical myelopathy secondary to violent tics of Tourette's syndrome
Dobbs and Berger
Neurology 2003;60:1862-1866.
FULL TEXT  

Tourette's Syndrome
Jankovic
NEJM 2001;345:1184-1192.
FULL TEXT  

Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial
Marras et al.
Neurology 2001;56:605-610.
ABSTRACT | FULL TEXT